Closing The Gap On Velcade, Proteolix Bags $79M In Series C
This article was originally published in The Pink Sheet Daily
Executive Summary
New proteasome inhibitor could dodge neuropathy side effect.
You may also be interested in...
Carfilzomib And Pomalidomide Pass Phase II
Proteolix’s novel proteasome inhibitor set for larger trial of relapsed, refractory myeloma.
Carfilzomib And Pomalidomide Pass Phase II
Proteolix’s novel proteasome inhibitor set for larger trial of relapsed, refractory myeloma.
ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma
At this year's American Society of Hematology meeting, scientists will present data suggesting a cocktail of Revlimid, Velcade and dexamethasone could emerge as the backbone of frontline therapy for multiple myeloma